Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast Calculation
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Polyclonal antibodies industry 3600 synopsis, 2018 – 2032 (USD Million)
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Product trends
2.1.4 Application trends
2.1.5 Route of administration trends
2.1.6 Source trends
2.1.7 End-user trends
Chapter 3 Polyclonal Antibodies Market Insights
3.1 Industry landscape, 2018 – 2032 (USD Million)
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of chronic and infectious diseases
3.2.1.2 Growing demand for personalized medicines
3.2.1.3 Increasing biopharmaceutical R&D activities
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringency of regulatory procedures
3.3 Growth potential analysis
3.3.1 By product
3.3.2 By application
3.3.3 By route of administration
3.3.4 By source
3.3.5 By end-users
3.4 COVID-19 impact analysis
3.5 Regulatory landscape
3.6 Porter’s analysis
3.7 PESTEL analysis
3.8 Pipeline Analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategic dashboard, 2022
Chapter 5 Polyclonal Antibodies Market Estimates and Forecast, By Product, 2018-2032 (USD Million)
5.1 Key trends, by product
5.2 Primary antibodies
5.3 Secondary antibodies
Chapter 6 Polyclonal Antibodies Market Estimates and Forecast, By Application, 2018-2032 (USD Million)
6.1 Key trends, by application
6.2 Diagnostics
6.3 Therapeutics
6.4 Research
Chapter 7 Polyclonal Antibodies Market Estimates and Forecast, By Route of Administration, 2018-2032 (USD Million)
7.1 Key trends, by route of administration
7.2 Intravenous (IV)
7.3 Subcutaneous (SC)
7.4 Other routes of administration
Chapter 8 Polyclonal Antibodies Market Estimates and Forecast, By Source, 2018-2032 (USD Million)
8.1 Key trends, by source
8.2 Rabbit
8.3 Goat
8.4 Mouse
8.5 Human
8.6 Other sources
Chapter 9 Polyclonal Antibodies Market Estimates and Forecast, By End-users, 2018-2032 (USD Million)
9.1 Key trends, by end-user
9.2 Pharmaceutical and Biotechnology Companies
9.3 Academic and Research Institutes
9.4 Contract Research Organizations (CROs)
9.5 Diagnostic Laboratories
9.6 Other end-users
Chapter 10 Polyclonal Antibodies Market Estimates and Forecast, By Region, 2018 - 2032 (USD Million)
10.1 Key trends, by region
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East & Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 Rest of Middle East & Africa
Chapter 11 Company Profiles
11.1 Thermo Fisher Scientific Inc.
11.2 F. Hoffmann-La Roche Ltd.
11.3 Merck Group (Merck KGaA)
11.4 Abcam plc
11.5 Bio-Rad Laboratories, Inc.
11.6 GenScript Biotech Corporation
11.7 Cell Signaling Technology, Inc.
11.8 Rockland Immunochemicals Inc.
11.9 BioLegend, Inc.
11.10 Santa Cruz Biotechnology, Inc.
11.11 Antibodies Inc.
11.12 Emergent
